It is also unclear whether the expression of the programmed death-ligand (PD-L1), which is routinely used to predict the benefit from immunotherapy in non-operable non-small cell lung cancer (NSCLC) [16], is of prognostic relevance for adjuvant lung cancer treatment. The gene discussed is CD274; the disease is lung carcinoma.